Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...
Cancer
ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...
Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...
Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...
Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...
Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China
At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced...
Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...
CStone Pharmaceuticals Presents CS5001 Clinical Data at the ASH Annual Meeting
China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on...
Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting
Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across...
BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval...
Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan
Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...
Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...
Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume
The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...